Jeff Settleman

Massachusetts General Hospital — United States

Medicine · Health Sciences

43h-index27.5kcitations224works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Lung Cancer Treatments and Mutations(66), Melanoma and MAPK Pathways(30), Computational Drug Discovery Methods(28), Cancer Mechanisms and Therapy(26), HER2/EGFR in Cancer Research(24)

Publications224 total

Suppl. Table 1 from Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers
2023Open Access
Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Figure Legends from Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers
2023Open Access
Supplementary Figure 8 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Figure 7 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Data from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Figure 3 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Dataset 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Figure 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Data from Cotargeting of MEK and PDGFR/STAT3 Pathways to Treat Pancreatic Ductal Adenocarcinoma
2023Open Access
Data from Ras–MEK Signaling Mediates a Critical Chk1-Dependent DNA Damage Response in Cancer Cells
2023Open Access
Supplementary Figure 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Suppl. Table 1 from Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers
2023Open Access
Supplementary Figure 8 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Figure Legends from Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers
2023Open Access
Data from Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers
2023Open Access
Suppl. Fig. 1-6 from Adapting a Drug Screening Platform to Discover Associations of Molecular Targeted Radiosensitizers with Genomic Biomarkers
2023Open Access
Supplementary Figure 3 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
Supplementary Dataset 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
2023Open Access
page 1 of 12Next →

Frequent Co-authors

Daniel A. Haber(8), Sreenath V. Sharma(6), Daphne W. Bell(5), Raffaella Sordella(5), Anurag Singh(5), Timothy R. Wilson(5), Eva Lin(5), Catherine Wilson(5), Robert L. Yauch(5), Brian W. Brannigan(4), Marie Classon(4), Mark Merchant(4), Richard M. Neve(4), Patricia Greninger(4), Cyril H. Benes(4), Benjamin Haley(4), Jean-Philippe Stéphan(4), Ross A. Okimoto(3), Ultan McDermott(3), Nabeel Bardeesy(3)